{
    "id": "d77f3b2f-eda8-45ae-8455-0fc1694fcd54",
    "indications": "ANDEXXA is indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.\n                  This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers [see Clinical Studies (14)]. An improvement in hemostasis has not been established.  Continued approval for this indication may be contingent upon the results of studies that demonstrate an improvement in hemostasis in patients.",
    "contraindications": "For intravenous (IV) use only. • Dose ANDEXXA based on the specific FXa inhibitor, dose of FXa inhibitor, and time since the patient's last dose of FXa inhibitor. ( 2 ) • Administer as an IV bolus, with a target rate of 30 mg/min, followed by continuous infusion for 120 minutes. ( 2.3 ) • There are two dosing regimens: Dose The safety and effectiveness of more than one dose have not been evaluated. ( 2.1 ) Initial IV Bolus Follow-On IV Infusion Low Dose 400 mg at a target rate of 30 mg/min 4 mg/min for 120 minutes High Dose 800 mg at a target rate of 30 mg/min 8 mg/min for 120 minutes",
    "adverseReactions": "None.",
    "ingredients": [
        {
            "name": "andexanet alfa",
            "code": "BI009E452R"
        }
    ],
    "organization": "AstraZeneca Pharmaceuticals LP",
    "name": "ANDEXXA",
    "effectiveTime": "20250523"
}